DDInter172 DDInter1771
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melatonin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Mephenytoin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Asparaginase Erwinia chrysanthemi
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi